Tomasetti Carmine, Autullo G, Ballerini A, de Bartolomeis A, Dell'Osso B, Fiorentini A, Tonioni F, Villari V, De Berardis D
Department of Mental Health, Alzheimer Center of Giulianova, Hospital "Maria SS dello Splendore", ASL Teramo, Giulianova (TE), Italy.
Psychiatry and Psychology Institute, Catholic University of Sacred Heart of Rome, Rome, Italy.
Ann Gen Psychiatry. 2024 May 30;23(1):21. doi: 10.1186/s12991-024-00507-z.
Personality disorders (PD) are described as enduring patterns of markedly deviant and pervasive inner experiences and behaviors, with onset in adolescence, which lead to severe distress or impairment. Patients suffering from major depressive disorder (MDD) display higher rates of comorbidity with personality disorders, often complicating the treatment, and worsening the outcomes. Borderline personality disorder (BPD) is the most common of PD and is frequently associated with MDD, with which shares several features. The most part of research agrees on the fact that comorbid BPD in MDD patients quite doubles the poor response to treatments. Moreover, no treatment strategy stands out currently to emerge as more effective in these cases, thus urging the call for the need of new approaches. Herein, we revise the current literature on BPD, its neurobiology and comorbidity with MDD, as well as the more recent treatment strategies used. Then, based on its pharmacology, we propose a possible role of trazodone as a valuable tool to approach comorbid BPD-MDD.
人格障碍(PD)被描述为明显偏离且普遍存在的内在体验和行为的持久模式,始于青春期,会导致严重的痛苦或功能损害。患有重度抑郁症(MDD)的患者与人格障碍的共病率更高,这常常使治疗复杂化,并使治疗结果恶化。边缘型人格障碍(BPD)是最常见的人格障碍,常与重度抑郁症相关,二者有若干共同特征。大部分研究都认同这样一个事实,即患有共病性边缘型人格障碍的重度抑郁症患者对治疗的不良反应几乎翻倍。此外,目前尚无突出的治疗策略在这些病例中显得更为有效,因此迫切需要新的治疗方法。在此,我们回顾了关于边缘型人格障碍、其神经生物学以及与重度抑郁症共病的现有文献,以及最近使用的治疗策略。然后,基于其药理学特性,我们提出曲唑酮作为一种有价值的工具来治疗边缘型人格障碍与重度抑郁症共病的可能作用。